このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC

2026年11月9日 更新者:Alice Shaw, MD、Dana-Farber Cancer Institute

TAP-ALK: A Phase I/II Study of TNG462 in Combination With Lorlatinib in MTAP-Deleted, ALK-Rearranged NSCLC Following Progression on Prior TKI Therapy

TAP-ALK is a DF/HCC investigator-sponsored interventional study of TNG462 (vopimetostat) in combination with lorlatinib for participants with MTAP-deleted, ALK-rearranged non-small cell lung cancer (NSCLC) following progression on prior tyrosine kinase inhibitor (TKI) therapy. The study is being conducted under IND 183798 and plans to enroll 30 participants.

調査の概要

状態

まだ募集していません

詳細な説明

This study evaluates a treatment regimen combining TNG462 and lorlatinib, both administered once daily per the consent study plan. Baseline assessments are performed before registration, with protocol-specified on-treatment visits during Cycle 1, Cycle 2, and subsequent cycles. Scheduled evaluations include physical examinations, vital signs, weight, performance status, laboratory testing, ECGs, adverse event review, and tumor measurements. Tumor imaging is repeated every 2 cycles for the first 6 months, then every 3 cycles thereafter. The consent form also describes optional tumor biopsies and optional plasma/serum collections for research.

For the Phase I portion, the protocol states that a BF-BOIN dose-escalation and backfilling design will be used, with no formal stratification factors applied to dose-escalation decisions.

研究の種類

介入

入学 (推定)

30

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • Dana Farber Cancer Institute
        • 主任研究者:
          • Alice Shaw, MD, PhD
        • コンタクト:
      • Boston、Massachusetts、アメリカ、02215

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age ≥ 18 years

  • Histologically or cytologically confirmed NSCLC harboring an ALK rearrangement, documented by an FDA/EMA-approved or validated local test.

  • Confirmed MTAP loss, demonstrated by immunohistochemistry (IHC) as complete loss in the presence of a positive internal control, or homozygous deletion by next-generation sequencing (NGS) in a CLIA-/ISO-accredited laboratory. The Sponsor-Investigator will review molecular testing to confirm eligibility (central reading of the IHC sample and/or repeat MTAP staining on archival tissue; check of the NGS report). Cases with heterogenous MTAP loss in IHC defined as MTAP loss in at least 80% of the tumor cells but less than 100%, may be included with the permission of the Sponsor-Investigator and after central revision of the slides.

  • Radiographic disease progression after at least one or more ALK TKIs, including prior lorlatinib therapy. Prior chemotherapy and prior neladalkib (NVL-655) are allowed

  • At least one measurable extracranial lesion according to RECIST v1.1.

  • ECOG performance status 0-1 (Appendix A). ECOG performance status 2 may be allowed with the permission of the Sponsor-Investigator

  • Adequate organ and marrow function, defined as:

    • ANC ≥ 1.5 × 10⁹/L
    • Platelets ≥ 75 × 10⁹/L, without platelet transfusion within 7 days prior to screening hematology assessment
    • Hemoglobin > 8.5 g/dL without transfusion within 14 days prior to screening hematology assessment
    • AST/ALT ≤ 2.5 × ULN (≤ 5 × ULN with documented liver metastases)
    • Total bilirubin ≤ 1.5 × ULN
    • Creatinine clearance ≥ 45 mL/min
  • Stable, previously treated brain metastases permitted if neurologically stable ≥ 2 weeks and on ≤ 10 mg prednisone equivalent. Untreated CNS metastases may be permitted with PI approval if: lesions are asymptomatic, ≤5 mm in size, no radiologic evidence of surrounding edema, and no current or anticipated need for corticosteroids.

  • Life expectancy ≥ 12 weeks.

  • Ability to swallow oral medication. TNG 462 tablets may be crushed and administered via NG-G tube if necessary, with written approval from Principal Investigator. Lorlatinib may not be crushed.

  • Written informed consent obtained prior to study procedures.

  • Participants must understand, sign and date the written informed consent form prior to any protocol-specific procedures performed. Participants should be able and willing to comply with study visits and procedures as per protocol

Exclusion Criteria:

  • 3.2.1 Prior treatment with a PRMT5 inhibitor, MAT2A inhibitor, or any investigational agent targeting the same pathway.

3.2.2 Prior treatment with lorlatinib resulting in discontinuation due to ≥ Grade 3 toxicity or with unresolved ≥ Grade 2 neurocognitive, pulmonary, or psychiatric adverse events at screening.

3.2.3 Ongoing or unresolved toxicity > Grade 1 from previous anticancer therapy (per CTCAE v5.0), except for the following: alopecia, endocrinopathies controlled by replacement therapy, or other protocol-allowed persistent Grade 2 toxicities (e.g., neuropathy) that, in the investigator's judgment, do not pose an unacceptable safety risk.

3.2.4 Major surgery within 4 weeks before first dose or incomplete recovery from surgery

3.2.5 Radiotherapy within 2 weeks before C1D1 (≤ 1 week for palliative RT ≤ 2 Gy/fraction); prior cranial RT permitted if completed ≥ 2 weeks before C1D1 and participant neurologically stable.

3.2.6 Concomitant use of strong or moderate CYP3A inhibitors or inducers, CYP3A or P-gp substrates with a narrow therapeutic index (e.g., digoxin, cyclosporine), or OATP1B3 substrates with a narrow therapeutic index (e.g. rosuvastatin, methotrexate, sirolimus), that cannot be discontinued or replaced.

3.2.7 Use of medications known to prolong QTc > 480 ms that cannot be safely discontinued.

  • Leptomeningeal carcinomatosis or spinal cord compression unless treated, clinically stable ≥ 4 weeks, and off steroids ≥ 14 days.
  • History of seizure disorder requiring enzyme-inducing antiepileptic drugs that cannot be substituted.
  • Baseline QTc > 480 ms (Fridericia), PR > 220 ms, clinically significant atrioventricular (AV) block, or uncontrolled arrhythmia.
  • History of myocardial infarction, unstable angina, coronary revascularization, stroke, or transient ischemic attack (TIA) within 6 months before C1D1.
  • Symptomatic congestive heart failure (NYHA ≥ Class II) or uncontrolled hypertension despite optimal medical therapy.
  • Interstitial lung disease, organizing pneumonia, or drug-induced pneumonitis, including prior lorlatinib-related pneumonitis, unless completely resolved.
  • Known HBsAg-positive or HCV RNA-positive infection with detectable viral load. Participant on suppressive antiviral therapy with undetectable viremia are eligible.
  • HIV infection with CD4 < 200/μL or on antiretrovirals that are strong CYP3A modulators.
  • Active uncontrolled infection requiring intravenous therapy within 7 days before C1D1.
  • Clinically significant gastrointestinal disorder that may affect absorption of oral medications (e.g., malabsorption syndrome, chronic diarrhea, short-bowel syndrome).
  • Uncontrolled hyperlipidemia defined as fasting total cholesterol > 300 mg/dL or triglycerides > 300 mg/dL despite medical management.
  • Clinically significant neurocognitive disorder, mood alteration, or psychiatric illness (including major depression or psychosis) that, in the investigator's judgment, could be exacerbated by lorlatinib or impair adherence.
  • Any other active malignancy within 2 years prior to enrollment, except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, early-stage prostate cancer undergoing active surveillance, curatively treated thyroid cancer, early stage breast cancer or DCIS, or any in situ cancers that have been treated with curative intent.
  • Pregnancy or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 7 days before first dose and agree to use two highly effective contraceptive methods during treatment and for ≥ 6 months after the last dose. Male participants must use effective contraception for ≥ 3 months after the last dose.
  • Known hypersensitivity to TNG462, lorlatinib, or any of their excipients.
  • Has any of the following: prior history of drug-induced or toxic retinopathy, or optic neuropathy; uncontrolled glaucoma; pre-existing macular degeneration; ongoing Grade ≥3 retinopathy, optic neuropathy, or optic neuritis; or any other known active retinal pathology.
  • Any condition (medical, psychiatric, social, or laboratory abnormality) that, in the opinion of the investigator, may confound study results, increase risk, or interfere with study compliance.
  • Participants who, in the investigator's or Sponsor-Investigator's judgment, are unable to comply with protocol requirements or whose participation would not be in their best interest may be excluded.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:TNG462 plus Lorlatinib

Participants receive TNG462 once daily and lorlatinib once daily according to the study treatment plan and study calendar.

Investigational drug Supplier/manufacturer: Tango Therapeutics

他の名前:
  • vopimetostat

Source/manufacturer: Commercial supply / Pfizer

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants Who Experience Dose-Limiting Toxicity (DLT)
時間枠:Up to 28 days.

A DLT is defined as a treatment-emergent adverse event occurring during Cycle 1 that is considered at least possibly related to TNG462, lorlatinib, or the combination and is not clearly attributable to underlying disease, intercurrent illness, or concomitant medications. DLTs include Grade ≥3 non-hematologic toxicities with specified exceptions for transient or manageable events; clinically significant hepatic, pulmonary, pancreatic, cardiac, ECG, CNS, or neurocognitive toxicities; Grade 4 hematologic toxicities; Grade ≥3 febrile neutropenia; Grade ≥3 thrombocytopenia with clinically significant bleeding; prolonged treatment-related hematologic toxicity requiring interruption of both study drugs for >14 consecutive days; any toxicity resulting in permanent discontinuation of both study drugs during Cycle 1 due to safety concerns; and any death at least possibly related to study treatment during the DLT assessment period.

Up to 28 days.
Maximum Tolerated Dose (MTD) of TNG462
時間枠:Up to 28 days.

The study uses a Backfill Bayesian Optimal Interval (BF-BOIN) design to determine the MTD of TNG462. TNG462 will start at 200 mg QD and may be escalated to 250 mg QD at the optional Dose Level 3 if Dose Level 2 is tolerated, at the discretion of the Sponsor-Investigator.

Up to 28 days.
MTD of Lorlatinib
時間枠:Up to 28 days.

The study uses a BF-BOIN design to determine the MTD of Lorlatinib. Lorlatinib will start at 50 mg QD and may be escalated to 75 mg QD at Dose Level 2 if Dose Level 1 is tolerated. Lorlatinib will remain at 75 mg QD at the optional Dose Level 3.

Up to 28 days.
Recommended Phase II Dose (RP2D) of TNG462 in Combination with Lorlatinib
時間枠:Up to 28 days.

The study uses a BF-BOIN design to determine the MTD. The RP2D is selected from among acceptable dose levels at or below the MTD based on the totality of safety, tolerability, pharmacokinetic, and preliminary antitumor activity data obtained during Phase I.

Up to 28 days.

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective response rate (ORR)
時間枠:Tumor measurements are repeated every 2 cycles for the first 6 months and every 3 cycles thereafter.

The study uses a BF-BOIN design to determine the MTD. The RP2D is selected from among acceptable dose levels at or below the MTD based on the totality of safety, tolerability, pharmacokinetic, and preliminary antitumor activity data obtained during Phase I.

ORR is defined as the proportion of patients achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.

Tumor measurements are repeated every 2 cycles for the first 6 months and every 3 cycles thereafter.
Duration of Overall Response (DOR)
時間枠:From date of first documented CR/PR until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

DOR based on Kaplan-Meier method is defined as the time from the first documented CR or PR until documented disease progression or death from any cause, whichever occurs first. Participants without disease progression or death will be censored at the date of their last disease evaluation.

From date of first documented CR/PR until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Median progression-free survival (PFS)
時間枠:From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

PFS based on Kaplan-Meier method is defined as the time from registration to progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.

From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
PFS Rate at 6 Months (PFS6)
時間枠:Up to 6 months.

PFS6 rate is defined as the proportion of evaluable participants who are alive and free of documented disease progression at 6 months after registration. articipants with documented disease progression or death from any cause before 6 months are considered non-responders. Participants who withdraw, are lost to follow-up, or lack adequate disease assessment before 6 months will be considered non-evaluable. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.

Up to 6 months.
Median Time to Treatment Failure (TTF)
時間枠:From date of registration until the date of first documented progression or date of death from any cause or permanent discontinuation of protocol therapy, or initiation of new cancer therapy, whichever came first, assessed up to 24 months

TTF based on the Kaplan-Meier method is defined as the time from registration to documented disease progression, death from any cause, permanent discontinuation of protocol therapy for toxicity or any other reason, or initiation of new systemic anticancer therapy, whichever occurs first. Participants who remain on protocol therapy without any of these events is censored at the date of their last protocol treatment administration.

From date of registration until the date of first documented progression or date of death from any cause or permanent discontinuation of protocol therapy, or initiation of new cancer therapy, whichever came first, assessed up to 24 months
Median Overall Survival (OS)
時間枠:From date of treatment initiation until the date of death from any cause, assessed up to 24 months

OS based on Kaplan-Meier method is defined as the time from treatment initiation until death due to any cause; participants who are alive at the time of analysis will be censored at the time of their last follow up.

From date of treatment initiation until the date of death from any cause, assessed up to 24 months
Central Nervous System (CNS)-Specific PFS
時間枠:From date of registration until the date of first documented intracranial progression or date of death from any cause, whichever came first, assessed up to 24 months

CNS-specific PFS based on Kaplan-Meier method is defined as the time from registration to the first documented intracranial disease progression or death from any cause, whichever occurs first. Intracranial progression is defined as progression of existing CNS lesions or the appearance of new CNS lesions according to RECIST v1.1 applied to CNS disease, as assessed by the investigator using protocol-mandated brain MRI. Participants without an event will be censored at the date of their last adequate CNS imaging assessment. Participants with extracranial-only progression will be censored at the date of their last CNS assessment.

From date of registration until the date of first documented intracranial progression or date of death from any cause, whichever came first, assessed up to 24 months
Trough Concentrations of TNG462 and Lorlatinib
時間枠:At day 22.

Trough concentrations are defined as the measured plasma concentrations of TNG462 and lorlatinib.

At day 22.
Central Nervous System (CNS) Adverse Event Rate
時間枠:AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

CNS-AE Rate is defined as the proportion of participants who experience a CNS adverse event. AEs are graded based on CTCAE v5.0.

AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
Hypercholesterolemia Rate
時間枠:AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

Hypercholesterolemia rate is defined as the proportion of participants who experience hypercholesterolemia. AEs are graded based on CTCAE v5.0.

AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
Hypertriglyceridemia Rate
時間枠:AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

Hypertriglyceridemia rate is defined as the proportion of participants who experience hypertriglyceridemia. AEs are graded based on CTCAE v5.0.

AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
Hepatotoxicity Rate
時間枠:AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

Hepatotoxicity rate is defined as the proportion of participants who experience hepatotoxicity. AEs are graded based on CTCAE v5.0.

AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
Interstitial Lung Disease or Pneumonitis Rate
時間枠:AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

Interstitial lung disease or pneumonitis rate is defined as the proportion of participants who experience interstitial lung disease or pneumonitis. AEs are graded based on CTCAE v5.0.

AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
Hematologic Toxicity Rate
時間枠:AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

Hematologic toxicity rate is defined as the proportion of participants who experience a hematologic toxicity. AEs are graded based on CTCAE v5.0.

AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Physical Functioning Scores
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Physical functioning is assessed using EORTC QLQ-C30. The physical functioning scale consists of 5 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better physical functioning.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Role Functioning Scores
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Role functioning is assessed using the EORTC QLQ-C30. The role functioning scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better role functioning.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Emotional Functioning Scores
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Emotional functioning is assessed using the EORTC QLQ-C30. The emotional functioning scale consists of 4 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better emotional functioning.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Cognitive Functioning Scores
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Cognitive functioning is assessed using the EORTC QLQ-C30. The cognitive functioning scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better cognitive functioning.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Social Functioning Scores
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Social functioning is assessed using the EORTC QLQ-C30. The social functioning scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better social functioning.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life Scores (QoL)
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Global health status/QoL is assessed using the EORTC QLQ-C30. The global health status/QoL scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better global health status and quality of life.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Fatigue Scores
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Fatigue is assessed using the EORTC QLQ-C30. The fatigue scale consists of 3 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater fatigue.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Nausea and Vomiting Scores
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Nausea and vomiting are assessed using the EORTC QLQ-C30. The nausea and vomiting scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater nausea and vomiting.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Pain Scores
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Pain is assessed using the EORTC QLQ-C30. The pain scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater pain.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Dyspnea Score
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Dyspnea is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater dyspnea.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Insomnia Score
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Insomnia is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater insomnia.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Appetite Loss Score
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Appetite loss is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater appetite loss.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Constipation Score
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Constipation is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater constipation.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Diarrhea Score
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Diarrhea is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater diarrhea.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change from Baseline in EORTC QLQ-C30 Financial Difficulties Score
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

Financial difficulties are assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater financial difficulties.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) Scores
時間枠:Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

The EORTC QLQ-LC13 is a 13-item lung cancer-specific questionnaire comprising symptom scales and single items. Each scale and item score is transformed to a range of 0 to 100, with higher scores indicating greater symptom burden.

Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Alice Shaw, MD, PhD、Dana-Farber Cancer Institute

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年4月30日

一次修了 (推定)

2027年11月30日

研究の完了 (推定)

2028年6月30日

試験登録日

最初に提出

2026年10月28日

QC基準を満たした最初の提出物

2026年11月9日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD 共有時間枠

Data can be shared no earlier than 1 year following the date of publication

IPD 共有アクセス基準

DFCI- Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する